Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Biogen in a research note ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...

Biogen (NASDAQ:BIIB – Get Free Report) had its target price lowered by equities researchers at Canaccord Genuity Group from ...

Scotiabank lowered the firm’s price target on Biogen (BIIB) to $224 from $244 and keeps an Outperform rating on the shares. Fiscal year results ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Biogen (BIIB – Research Report) yesterday. The company’s shares closed yesterday at ...